Skip to content

Bionano Genomics, Inc.: 10-K filed 2020-03-10

What Bionano Genomics, Inc. reported in its annual report filed 2020-03-10 (fiscal FY 2019): 40 published measures, 97 facts as tagged in accession 0001411690-20-000006.

This filing

Form
10-K (annual report)
Filed
2020-03-10
Fiscal period
fiscal FY 2019
Accession
0001411690-20-000006 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Bionano Genomics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-12-3130,207,866USD
At 2018-12-3124,802,421USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-12-3126,594,148USD
At 2018-12-3114,665,070USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-12-313,613,718USD
At 2018-12-3110,137,351USD
At 2017-12-31-50,227,211USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-12-3117,311,373USD
At 2018-12-3116,522,729USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-10-01 to 2019-12-31-7,900,595USD92
2019-01-01 to 2019-12-31-29,815,070USD365
2019-07-01 to 2019-09-30-6,398,166USD92
2019-04-01 to 2019-06-30-7,664,566USD91
2019-01-01 to 2019-03-31-7,851,743USD90
2018-10-01 to 2018-12-31-6,411,457USD92
2018-01-01 to 2018-12-31-18,496,392USD365
2018-07-01 to 2018-09-30-4,926,097USD92
2018-04-01 to 2018-06-30-3,311,476USD91
2018-01-01 to 2018-03-31-3,847,362USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-29,529,720USD365
2018-01-01 to 2018-12-31-19,943,847USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2019-01-01 to 2019-12-3161,056USD365
2018-01-01 to 2018-12-31331,716USD365

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2019-10-01 to 2019-12-312,789,130USD92
2019-01-01 to 2019-12-3110,129,508USD365
2019-07-01 to 2019-09-303,312,997USD92
2019-04-01 to 2019-06-302,174,635USD91
2019-01-01 to 2019-03-311,852,746USD90
2018-10-01 to 2018-12-314,013,537USD92
2018-01-01 to 2018-12-3112,000,735USD365
2018-07-01 to 2018-09-302,828,704USD92
2018-04-01 to 2018-06-303,390,009USD91
2018-01-01 to 2018-03-311,768,485USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-12-3130,379,420USD365
2018-01-01 to 2018-12-3135,776,395USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-61,056USD365
2018-01-01 to 2018-12-31-331,716USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-12-31-102,577,498USD
At 2018-12-31-72,762,428USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2019-01-01 to 2019-12-3121,048USD365
2018-01-01 to 2018-12-3115,511USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-12-311,949,625USD
At 2018-12-311,777,302USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-01-01 to 2019-12-311,346,023USD365
2018-01-01 to 2018-12-311,193,873USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-25,874,906USD365
2018-01-01 to 2018-12-31-20,415,085USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-12-3128,258,241USD
At 2018-12-3123,025,119USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-01-01 to 2019-12-312,286,196USD365
2018-01-01 to 2018-12-311,381,024USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-12-3126,367,021USD
At 2018-12-314,522,863USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-12-312,699,153USD
At 2018-12-311,351,736USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2019-12-316,333,963USD
At 2018-12-314,514,333USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2019-12-313,443,559USD
At 2018-12-311,068,557USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2019-01-01 to 2019-12-3120,155,376USD365
2018-01-01 to 2018-12-3114,220,331USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-01-01 to 2019-12-319,080,891USD365
2018-01-01 to 2018-12-319,484,163USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-12-3134,274,469shares
At 2018-12-3110,055,072shares

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2019-12-3120,084,945USD
At 2018-12-319,029,374USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2019-12-318,223,091USD
At 2018-12-316,939,666USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2019-12-316,273,466USD
At 2018-12-315,162,364USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2019-12-3144,479USD
At 2018-12-31808,366USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2019-12-313,225,431USD
At 2018-12-312,900,129USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-12-311,169,346USD
At 2018-12-31919,500USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2019-12-310USD
At 2018-12-310USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-29,794,022USD365
2018-01-01 to 2018-12-31-18,480,881USD365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-29,815,070USD365
2018-01-01 to 2018-12-31-18,496,392USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2019-01-01 to 2019-12-311,127,850USD365
2018-01-01 to 2018-12-311,320,521USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-3,919,116USD365
2018-01-01 to 2018-12-311,934,204USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2019-01-01 to 2019-12-3121,048USD365
2018-01-01 to 2018-12-3115,511USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2019-01-01 to 2019-12-311,277,184USD365
2018-01-01 to 2018-12-31700,353USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-312,374,497USD365
2018-01-01 to 2018-12-31900,119USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-313,641,017USD365
2018-01-01 to 2018-12-31418,984USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-311,362,397USD365
2018-01-01 to 2018-12-31-954,377USD365

Inspect the source

Entity
Bionano Genomics, Inc. / CIK 0001411690
Captured
SEC response SHA-256
de1f7683e64ca05fd1e6239a8009bb07a28d93e0115f74423aec0ba56b765b33

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001411690.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))